-
- Rasoul Mirzaei
- Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
-
- Pedram Goodarzi
- Faculty of Pharmacy Iran University of Medical Sciences Tehran Iran
-
- Muhammad Asadi
- Faculty of Medicine Iran University of Medical Sciences Tehran Iran
-
- Ayda Soltani
- School of Basic Sciences Ale‐Taha Institute of Higher Education Tehran Iran
-
- Hussain ali abraham Aljanabi
- Faculty of Medicine Iran University of Medical Sciences Tehran Iran
-
- Ali Salimi Jeda
- Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran
-
- Shirin Dashtbin
- Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
-
- Saba Jalalifar
- Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
-
- Rokhsareh Mohammadzadeh
- Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
-
- Ali Teimoori
- Department of Virology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
-
- Kamran Tari
- Student Research Committee Hamadan University of Medical Sciences Hamadan Iran
-
- Mehdi Salari
- Student Research Committee Hamadan University of Medical Sciences Hamadan Iran
-
- Sima Ghiasvand
- Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
-
- Sima Kazemi
- Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
-
- Rasoul Yousefimashouf
- Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
-
- Hossein Keyvani
- Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran
-
- Sajad Karampoor
- Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran
説明
<jats:title>Abstract</jats:title><jats:p>The pandemic coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID‐19 are underway. Respiratory viral infections, such as influenza, predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS‐CoV‐2). Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. Also, the antibiotic‐resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19.</jats:p>
収録刊行物
-
- IUBMB Life
-
IUBMB Life 72 (10), 2097-2111, 2020-08-08
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360013198955564288
-
- DOI
- 10.1002/iub.2356
-
- ISSN
- 15216551
- 15216543
-
- データソース種別
-
- Crossref